Amineptine was developed by the French Society of Medical research in the 1960s.[6] Introduced in France in 1978 by the
pharmaceutical company
Servier,[7] amineptine soon gained a reputation for abuse due to its short-lived, but pleasant,
stimulant effect experienced by some patients.
After its release into the
European market, cases of
hepatotoxicity emerged, some serious. This, along with the potential for abuse, led to the suspension of the French marketing authorization for Survector in 1999.[8]
Amineptine is illegal in both Germany and the United States.
Medical uses
Amineptine was approved in France for severe
clinical depression of endogenous origin in 1978.[9]
Severe
acne due to amineptine was first reported in 1988 by various authors—Grupper, Thioly-Bensoussan, Vexiau, Fiet, Puissant, Gourmel, Teillac, Levigne, to name a few—simultaneously[11][12][13][14][15] in the same issue of Annales de Dermatologie et de Vénéréologie and in the 12 March 1988 issue of The Lancet.[16] A year later, Dr Martin-Ortega and colleagues in Barcelona, Spain reported a case of "acneiform eruption" in a 54-year-old woman whose intake of amineptine was described as "excessive."[17] One year after that, Vexiau and colleagues reported six women, one of whom never admitted to using amineptine, getting severe acne concentrated in the face, back and
thorax, the severity of which varied with the dosage.[18] Most of them were treated unsuccessfully with
isotretinoin (Accutane) for about 18 months; two of the three that discontinued amineptine experienced a reduction in cutaneous symptoms, with the least affected patient going into remission.[18]
Psychiatric
Psychomotor excitation can very rarely occur with this drug.
Suicidal ideation. Seen early in the treatment, by lifting of psychomotor inhibition.
Abuse and dependence
The risk of
addiction is low, but exists nonetheless. Between 1978 and 1988, there were 186 cases of amineptine addiction reported to the French Regional Centres of Pharmacovigilance; an analysis of 155 of those cases found that they were predominantly female, and that two-thirds of cases had known risk factors for addiction.[19] However, a 1981 study of known
opiate addicts and
schizophrenia patients found no drug addiction in any of the subjects.[20] In a 1990 study of eight amineptine dependence cases, the gradual withdrawal of amineptine could be achieved without problems in six people; in two others,
anxiety, psychomotor agitation, and/or
bulimia appeared.[21]
Withdrawal
Pharmacodependence is very common with amineptine compared to other antidepressants.[22] A variety of psychological symptoms can occur during withdrawal from amineptine,[23] such as
anxiety and agitation.[24]
Amineptine can rarely cause
hepatitis, of the
cytolytic,
cholestatic varieties.[25] Amineptine-induced hepatitis, which is sometimes preceded by a rash, is believed to be due to an immunoallergic reaction.[26] It resolves upon discontinuation of the offending drug.[25] The risk of getting this may or may not be genetically determined.[27]
Mixed hepatitis, which is very rare, generally occurs between the 15th and 30th day of treatment. Often preceded by sometimes intense abdominal pains, nausea, vomiting or a rash, the jaundice is variable. Hepatitis is either of mixed type or with cholestatic prevalence. The evolution was, in all the cases, favorable to the discontinuation of the drug. The mechanism is discussed (immunoallergic and/or toxic).[29]
In circa 1994 Spain, there was a case associating acute pancreatitis and mixed hepatitis, after three weeks of treatment.[30]
Lazaros and colleagues at the Western Attica General Hospital in
Athens, Greece reported two cases of drug induced hepatitis 18 and 15 days of treatment.[31]
One case of cytolytic hepatitis occurred after ingestion of only one tablet.[32]
Gastrointestinal
Acute pancreatitis (very rare) A case associating acute
pancreatitis and mixed hepatitis after three weeks of treatment.[30]
No human data appear to be available for binding or inhibition of the
monoamine transporters by amineptine.[43]
Pharmacokinetics
Peak plasma levels of amineptine following a single 100 mg oral dose have been found to range between 277 and 2,215 ng/mL (818–6,544 nM), with a mean of 772 ng/mL (2,281 nM), whereas maximal plasma concentrations of its major
metabolite ranged between 144 and 1,068 ng/mL (465–3,452 nM), with a mean of 471 ng/mL (1,522 nM).[2] After a single 200 mg oral dose of amineptine, mean peak plasma levels of amineptine were around 750 to 940 ng/mL (2,216–2,777 nM), while those of its major metabolite were about 750 to 970 ng/mL (2,216–3,135 nM).[3] The
time to peak concentrations is about 1 hour for amineptine and 1.5 hours for its major metabolite.[2][3] The
elimination half-life of amineptine is about 0.80 to 1.0 hours and that of its major metabolite is about 1.5 to 2.5 hours.[2][3] Due to their very short elimination half-lives, amineptine and its major metabolite do not accumulate significantly with repeated administration.[2]
Society and culture
Brand names
Amineptine has been sold under a variety of brand names including Survector, Maneon, Directim, Neolior, Provector, and Viaspera.
^
abVaugeois JM, Corera AT, Deslandes A, Costentin J (June 1999). "Although chemically related to amineptine, the antidepressant tianeptine is not a dopamine uptake inhibitor". Pharmacology Biochemistry and Behavior. 63 (2): 285–90.
doi:
10.1016/S0091-3057(98)00242-1.
PMID10371658.
S2CID32862145.
^Grupper C (1988). "[New iatrogenic acne: acne caused by amineptin (Survector)]". Annales de Dermatologie et de Vénéréologie (in French). 115 (11): 1174–6.
PMID2977079.
^Thioly-Bensoussan D, Charpentier A, Triller R, et al. (1988). "[Iatrogenic acne caused by amineptin (Survector). Apropos of 8 cases]". Annales de Dermatologie et de Vénéréologie (in French). 115 (11): 1177–80.
PMID2977080.
^Vexiau P, Gourmel B, Husson C, et al. (1988). "[Severe lesions of acne type induced by chronic amineptin poisoning: apropos of 6 cases]". Annales de Dermatologie et de Vénéréologie (in French). 115 (11): 1180–2.
PMID2977081.
^Teillac D, Weber MJ, Lowenstein W, de Prost Y (1988). "[Acne caused by Survector]". Annales de Dermatologie et de Vénéréologie (in French). 115 (11): 1183–4.
PMID2977082.
^Lévigne V, Faisant M, Mourier C, et al. (1988). "[Monstrous acne in the adult. Inducer role of Survector?]". Annales de Dermatologie et de Vénéréologie (in French). 115 (11): 1184–5.
PMID2977083.
^Martín-Ortega E, Zamora E, Herrero C, Palou J (1989). "[Acneiform eruption induced by amineptin (Survector)]". Medicina Cutánea Ibero-latino-americana (in Spanish). 17 (6): 414–6.
PMID2534534.
^
abVexiau P, Gourmel B, Castot A, et al. (1990). "Severe acne due to chronic amineptine overdose". Archives of Dermatological Research. 282 (2): 103–7.
doi:
10.1007/BF00493467.
PMID2141246.
S2CID39394890.
^Castot A, Benzaken C, Wagniart F, Efthymiou ML (1990). "[Amineptin abuse. Analysis of 155 cases. An evaluation of the official cooperative survey of the Regional Centers of Pharmacovigilance]". Thérapie (in French). 45 (5): 399–405.
PMID2260032.
^Deniker P, Lôo H, Zarifian E, et al. (1981). "[Amineptine and amotival syndrome (author's transl)]". L'Encéphale (in French). 7 (1): 59–64.
PMID7227285.
^Bertschy G, Luxembourger I, Bizouard P, Vandel S, Allers G, Volmat R (1990). "[Amineptin dependence. Detection of patients at risk. Report of 8 cases]". L'Encéphale (in French). 16 (5): 405–9.
PMID2265603.
^Blayac JP, Hillaire-Buys D, Peyrière H (1997). "[Pharmacovigilance of new antidepressants: evaluation of neuro-psychobehavioral disorders]". Thérapie. 52 (2): 117–22.
PMID9231505.
^Castot A, Benzaken C, Wagniart F, Efthymiou ML (1990). "[Amineptin abuse. Analysis of 155 cases. An evaluation of the official cooperative survey of the Regional Centers of Pharmacovigilance]". Thérapie. 45 (5): 399–405.
PMID2260032.
^Bertschy G, Luxembourger I, Bizouard P, Vandel S, Allers G, Volmat R (1990). "[Amineptin dependence. Detection of patients at risk. Report of 8 cases]". L'Encéphale. 16 (5): 405–9.
PMID2265603.
^
abBories P, Pomier-Layrargues G, Chotard JP, et al. (December 1980). "[Amineptine-induced cholestatic hepatitis. 5 cases (author's transl)]". La Nouvelle Presse Médicale (in French). 9 (48): 3689–92.
PMID7454584.
^Pessayre D, Larrey D (April 1988). "Acute and chronic drug-induced hepatitis". Baillière's Clinical Gastroenterology. 2 (2): 385–422.
doi:
10.1016/0950-3528(88)90009-7.
PMID3044468.
^Larrey D, Pageaux GP (1997). "Genetic predisposition to drug-induced hepatotoxicity". Journal of Hepatology. 26 (Suppl 2): 12–21.
doi:
10.1016/S0168-8278(97)80492-8.
PMID9204405.
^
abSebastián Domingo JJ, Simón Marco MA, Uribarrena Echebarría R (March 1994). "Hepatic and pancreatic injury associated with amineptine therapy". Journal of Clinical Gastroenterology. 18 (2): 168–9.
doi:
10.1097/00004836-199403000-00023.
PMID8189020.
^Lazaros GA, Stavrinos C, Papatheodoridis GV, Delladetsima JK, Toliopoulos A, Tassopoulos NC (1996). "Amineptine induced liver injury. Report of two cases and brief review of the literature". Hepato-gastroenterology. 43 (10): 1015–9.
PMID8884331.
^Jonville AP, Dutertre JP, Autret E (1992). "[Immediate acute hepatic cytolysis after the administration of a single amineptin tablet]". Gastroentérologie Clinique et Biologique (in French). 16 (4): 368.
PMID1397859.
^Roth BL, Driscol, J.
"PDSP Ki Database". Psychoactive Drug Screening Program (PDSP). University of North Carolina at Chapel Hill and the United States National Institute of Mental Health. Retrieved 14 August 2017.
^
abNishino S, Mao J, Sampathkumaran R, Shelton J (1998). "Increased dopaminergic transmission mediates the wake-promoting effects of CNS stimulants". Sleep Res Online. 1 (1): 49–61.
PMID11382857.
^Protais P, Arbaoui J, Bakkali EH, Bermejo A, Cortes D (1995). "Effects of various isoquinoline alkaloids on in vitro 3H-dopamine uptake by rat striatal synaptosomes". J. Nat. Prod. 58 (10): 1475–84.
doi:
10.1021/np50124a001.
PMID8676127.
^
abcdefghiHall H, Sällemark M, Wedel I (1984). "Acute effects of atypical antidepressants on various receptors in the rat brain". Acta Pharmacol Toxicol (Copenh). 54 (5): 379–84.
doi:
10.1111/j.1600-0773.1984.tb01945.x.
PMID6464782.
^
abHall H, Ogren SO (1984). "Effects of antidepressant drugs on histamine-H1 receptors in the brain". Life Sci. 34 (6): 597–605.
doi:
10.1016/0024-3205(84)90494-6.
PMID6141518.
^Andersen J, Kristensen AS, Bang-Andersen B, Strømgaard K (2009). "Recent advances in the understanding of the interaction of antidepressant drugs with serotonin and norepinephrine transporters". Chem. Commun. (25): 3677–92.
doi:
10.1039/b903035m.
PMID19557250.